Product Description
Product Name: Eleftha 440 mg Injection
Active Ingredient: Trastuzumab
Strength: 440 mg
Form: Lyophilized Powder for Intravenous Infusion
Category: Anticancer / HER2-Targeted Monoclonal Antibody
Indication: HER2-Positive Breast Cancer and Gastric (Stomach) Cancer
Eleftha 440 mg Injection contains Trastuzumab, a targeted therapy used in the treatment of HER2-positive breast cancer and HER2-overexpressing metastatic gastric cancer. It is a recombinant humanized monoclonal antibody that binds specifically to the HER2/neu receptor, inhibiting cancer cell growth and survival.
Mechanism of Action:
By targeting the HER2 receptor, Trastuzumab blocks proliferative signals and enhances immune-mediated destruction of cancer cells.
